FATE
Fate Therapeutics, Inc.
Healthcare · Biotechnology · NGM
$1.98
Data: 2026-05-13
✗ ETHICAL FAIL

MOAT
HIGH
Data Confidence: 100.0%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$248M
Total market value of the company
Trailing P/E
0.00
Forward P/E
-2.04
Based on estimated future earnings — lower means cheaper
Rev Growth
-26.4%
Year-over-year revenue change
Profit Margin
0.0%
How much profit the company keeps from each dollar of revenue
ROE
-51.8%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$5.44
+175% from current price — median analyst estimate
Recommendation
BUY
Consensus view from 8 analysts covering this stock
About Fate Therapeutics, Inc.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.

https://www.fatetherapeutics.com

Country: United States Employees: 161 Industry: Biotechnology
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
31.4% PASS
Debt must be below 33% of total assets
Cash Ratio
82.0% FAIL
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
MARKUP
Price trending up with increasing momentum
Sharpe Ratio
0.227
Positive but modest risk-adjusted returns
Kelly Fraction
-0.0249
No positive edge detected — the data suggests staying out
Calmar Ratio
-0.253
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-22.2%
Historical annualised return based on price data
Max Drawdown
-87.8%
Largest peak-to-trough decline — the worst it has been
HMM State
BEAR
Statistical model detects bearish conditions
Days in State
14
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
2.14
Significantly more volatile than the market
52W High
$2.47
20% below the year high
52W Low
$0.91
118% above the year low
Avg Volume
2,064,050
Average daily shares traded — higher means easier to buy and sell
Short Ratio
8.9
Days it would take all short sellers to cover — higher means more crowded
Short % Float
10.0%
Moderate short interest
Div Yield
0.0%
Annual dividend as a percentage of the share price
EPS (TTM)
$-1.15
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
0.38
Conservative use of debt — low financial risk
Current Ratio
5.85
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
5.75
Like current ratio but excludes inventory — stricter test
Gross Margin
N/A
Revenue left after cost of goods — higher means pricing power
Operating Margin
-2,540.4%
Profit from core operations before interest and tax
Free Cash Flow
$-50,068,500
Negative — the business is spending more than it generates
Revenue (TTM)
$6M
Total revenue over the last 12 months
Net Income
$-129,907,000
Loss-making — spending exceeds revenue after all costs
Analyst Coverage
Analysts
8
Target High
$8.00
Target Median
$5.44
Target Low
$2.00
Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date Insider Title Type Shares Value
2026-05-20 TAHL CINDY R Officer 25,590 $48,084
2026-05-20 VALAMEHR BAHRAM Chief Executive Officer 28,946 $54,482
2026-05-06 TAHL CINDY R Officer 166,664 $207,997
2026-05-05 RASTETTER WILLIAM H Director 25,000 $42,250
2026-05-05 EPSTEIN ROBERT S Director 25,000 $42,250
2026-01-15 TAHL CINDY R Officer 100,000 —
2026-01-15 VALAMEHR BAHRAM Chief Executive Officer 335,000 —
2026-01-15 ADAWI KAMAL Chief Financial Officer 25,000 —
2026-01-09 TAHL CINDY R Officer 10,589 $11,275
2026-01-09 VALAMEHR BAHRAM Chief Executive Officer 5,190 $5,557
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-13

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.